Performance in Delivering Clinical Research Q2 2014-15
Time to Target (Commercial Contracts)

Research Ethics Committee Number	Trial Name	Target number of patients	Recruitment end date	Trial Status	Target met ?	Comments
10/H0606/69	RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics - Protocol No. NN25310	6	08/05/2013	Closed - Follow Up Complete	No	Four participants recruited from six, viewed as successful by the sponsor. Schizophrenia patients are particularly hard to recruit.
10/H0604/94	RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics. Protocol No. NN25307	6	30/06/2013	Closed - Follow Up Complete	No	Schizophrenia patients are particularly hard to recruit and this diagnosis as an inclusion criteria compounds the difficulty.
11/SC/0383	Evaluation of the effects of agomelatine (25mg and 50mg) and escitalopram 20mg during 8 weeks on emotional blunting, emotional processing and motivation in healthy male and female volunteers.	64	22/03/2013	Closed - Follow Up Complete	Yes	Healthy volunteers not patients
12/SC/0213	Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of LuAA21004 on cognition and BOLD fMRI signals in subjects remitted from depression and controls	32	05/04/2013	Closed - Follow Up Complete	No	Recuited 30 participants of the 32. There was difficulty recruiting the last two controls, another UK site agreed to do this and total target for the study in the UK was met
12/SC/0544	A randomised, double-blind, placebo-controlled, dose-ranging, parallel-group, phase 2 study of the safety and efficacy of ABT-126 in the treatment of cognitive deficits in schizophrenia (CDS) in nonsmokers	3	03/01/2014	Closed - Follow Up Complete	No	Recruited 2 out of 3 patients. Patients with schizophrenia are particularly difficult to recruit. This study required patients with schizophrenia who were also non-smokers, which was difficult to achieve given that approximately two thirds of patients with schizophenia smoke (NICE, 2004; Smoking and Mental Health fact sheet)
12/NE/0410	A randomised, placebo-controlled, parallel-group, double-blind, efficacy and safety trial of MK-8931 in subjects with mild to moderate Azheimer's disease	8	23/12/2016	Open	N/A	
12/EM/0391	A randomised, double blind, placebo controlled, phase 3 study to evaluate the efficacy and safety of once a day, TAK375 (Ramelteon) tablet for sub-lingual administration (TAK375SL tablet) 0.1mg and 0.4mg as an adjunctive therapy in the treatment of acute depressive episodes associated with Bipolar 1 disorder in adult subjects	5	05/11/2014	Withdrawn	No	Sponsor closed the study early following interim analysis and recommendation from the DMC that the pre-determined efficacy criteria for study termination had been met.
13/SC/0386	Long term safety and efficacy of ABT-126 in subjects with schizophrenia: a double-blind extension study for subjects completing study M10-855	2	31/03/2015	Closed - Follow Up Complete	No	Only 1 participant was eligible to proceed to the extension study. The 2nd potentially eligible participant withdrew consent to enter the extension study.
13/NW/0727	A randomised, double-blind, placebo-controlled, single-dose, study of the effects of SEP 363856 and Amisulpride on bold-FMRI signal in healthy male and female volunteers with high or low schizotype characteristics	54	29/05/2015	Open	N/A	
13/LO/1758	A phase III. randomised, placebo controlled, parallel group, double blind clinical trial to study the efficacy and safety of MK8931 (SCH 900931) in subjects with amnestic mild cognitive impairment due to Alzheimer's Disease (Prodromal AD)	6	31/03/2016	Open	N/A	